{"id":"NCT02203838","sponsor":"Indivior Inc.","briefTitle":"Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia","officialTitle":"An Open-Label, Long-Term Safety and Tolerability Study of RBP-7000 in the Treatment of Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2016-09","completion":"2016-09","firstPosted":"2014-07-30","resultsPosted":"2018-09-28","lastUpdate":"2018-09-28"},"enrollment":500,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"RBP-7000","otherNames":["Risperidone","Long-acting Risperidone"]}],"arms":[{"label":"RBP-7000 - 120-mg dose","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with schizophrenia and to continue collecting clinical outcome data with RBP-7000 SC injections in subjects with schizophrenia using the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity Illness (CGI-S) scale.","primaryOutcome":{"measure":"Participants With Treatment-Emergent Adverse Events (TEAE)","timeFrame":"Day 1 up to week 52","effectByArm":[{"arm":"De Novo Participants","deltaMin":306,"sd":null},{"arm":"Rollover Placebo","deltaMin":21,"sd":null},{"arm":"Rollover RBP-7000 90 mg","deltaMin":22,"sd":null},{"arm":"Rollover RBP-7000 120 mg","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":48,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":408},"commonTop":["Injection site pain","Weight increased","Insomnia","Injection site nodule","Schizophrenia"]}}